Trial Profile

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 May 2025 Planned End Date changed from 19 Jan 2025 to 7 Apr 2030.
30 Apr 2025 Results (n=70) of an analysis of specific B cell subsets, as predictive and pharmacodynamic biomarkers for irAEs in a phase II trial combining nivolumab (3 mg/kg), ipilimumab(1 mg/ml), and the IL-6 receptor inhibitor tocilizumab (4 mg/kg) in unresectable/advanced stage III/IV melanoma patients presented at the 116th Annual Meeting of the American Association for Cancer Research.
15 Aug 2024 Planned End Date changed from 1 Nov 2024 to 19 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com